Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Buy
66
SRPT Quote, Financials, Valuation and Earnings
Last price:
$62.03
Seasonality move
:
13.61%
Day range:
$60.18 - $62.47
52-week range:
$48.01 - $173.25
Dividend yield:
0%
P/E ratio:
26.98x
P/S ratio:
3.61x
P/B ratio:
3.91x
Volume:
1.2M
Avg. volume:
3M
1-year change:
-52.23%
Market cap:
$6B
Revenue:
$1.9B
EPS (TTM):
$2.28
Analysts' Opinion
-
Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $147.33, Sarepta Therapeutics has an estimated upside of 139.53% from its current price of $61.51.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $70.00 representing 100% downside risk from its current price of $61.51.
Fair Value
-
According to the consensus of 18 analysts, Sarepta Therapeutics has 139.53% upside to fair value with a price target of $147.33 per share.
SRPT vs. S&P 500
-
Over the past 5 trading days, Sarepta Therapeutics has overperformed the S&P 500 by 8.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sarepta Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sarepta Therapeutics has grown year-over-year revenues for 29 quarters straight. In the most recent quarter Sarepta Therapeutics reported revenues of $658.4M.
Earnings Growth
-
Sarepta Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sarepta Therapeutics reported earnings per share of $1.50.
Enterprise value:
5.8B
EV / Invested capital:
--
Price / LTM sales:
3.61x
EV / EBIT:
20.60x
EV / Revenue:
3.02x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-16.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
18.15x
Gross Profit (TTM):
$1.6B
Return On Assets:
6.73%
Net Income Margin (TTM):
12.37%
Return On Equity:
20.83%
Return On Invested Capital:
10.04%
Operating Margin:
24.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $933M | $1.2B | $1.9B | $396.8M | $658.4M | |
| Gross Profit | $793M | $1.1B | $1.6B | $352.6M | $526.1M | |
| Operating Income | -$536.2M | -$267.8M | $218.1M | $24.6M | $161.7M | |
| EBITDA | -$594.9M | -$453.7M | $316.9M | $57M | $186.7M | |
| Diluted EPS | -$8.03 | -$5.83 | $2.28 | $0.76 | $1.50 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5B | $2.6B | $2.6B | $2.6B | $3.1B | |
| Total Assets | $3B | $3.1B | $3.1B | $3.3B | $4B | |
| Current Liabilities | $416M | $452.7M | $619.6M | $653.7M | $731.7M | |
| Total Liabilities | $2.2B | $2.2B | $2.7B | $2.4B | $2.4B | |
| Total Equity | $761.8M | $928M | $385M | $859.3M | $1.5B | |
| Total Debt | $992.5M | $1.1B | $1.5B | $1.2B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$325.3M | -$501M | -$205.8M | -$54.7M | $92M | |
| Cash From Investing | -$1B | -$165.8M | $755.6M | -$64.4M | $764.1M | |
| Cash From Financing | $232.5M | $125M | $124.8M | $1.9M | $49M | |
| Free Cash Flow | -$357.6M | -$588.3M | -$352.7M | -$73.7M | $54M | |
SRPT
Sector
Market Cap
$6B
$34.4M
Price % of 52-Week High
35.5%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-52.23%
-39.44%
Beta (5-Year)
0.930
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$58.18
200-day SMA
Sell
Level
$115.66
Bollinger Bands (100)
Sell
Level
74.34 - 126.84
Chaikin Money Flow
Sell
Level
-80.3M
20-day SMA
Buy
Level
$56.72
Relative Strength Index (RSI14)
Sell
Level
45.08
ADX Line
Sell
Level
42.52
Williams %R
Sell
Level
-8.5985
50-day SMA
Sell
Level
$79.93
MACD (12, 26)
Sell
Level
-5.32
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
381.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8366)
Sell
CA Score
(Annual)
Level (-0.6899)
Sell
Beneish M-Score
(Annual)
Level (-1.4539)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.1179)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Stock Forecast FAQ
In the current month, SRPT has received 14 Buy ratings 4 Hold ratings, and 0 Sell ratings. The SRPT average analyst price target in the past 3 months is $147.33.
-
Where Will Sarepta Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sarepta Therapeutics share price will rise to $147.33 per share over the next 12 months.
-
What Do Analysts Say About Sarepta Therapeutics?
Analysts are divided on their view about Sarepta Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sarepta Therapeutics is a Sell and believe this share price will drop from its current level to $70.00.
-
What Is Sarepta Therapeutics's Price Target?
The price target for Sarepta Therapeutics over the next 1-year time period is forecast to be $147.33 according to 18 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is SRPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sarepta Therapeutics is a Buy. 14 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SRPT?
You can purchase shares of Sarepta Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sarepta Therapeutics shares.
-
What Is The Sarepta Therapeutics Share Price Today?
Sarepta Therapeutics was last trading at $62.03 per share. This represents the most recent stock quote for Sarepta Therapeutics. Yesterday, Sarepta Therapeutics closed at $61.51 per share.
-
How To Buy Sarepta Therapeutics Stock Online?
In order to purchase Sarepta Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 8.47% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 1.78% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is up 0.32% over the past day.
